Demethylenetetrahydroberberine protects dopaminergic neurons in a mouse model of Parkinson's disease.
10.1016/S1875-5364(22)60145-6
- Author:
Jing WEN
1
;
Yuan-Qiang ZHANG
1
;
Dong-Qing LIU
1
;
Xu-Tao YAO
1
;
Hua JIANG
1
;
Yu-Bin ZHANG
2
Author Information
1. Department of Biochemistry, School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China.
2. Department of Biochemistry, School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China. Electronic address: ybzhang@cpu.edu.cn.
- Publication Type:Journal Article
- Keywords:
Apoptosis;
Demethylenetetrahydroberberine;
Dopaminergic neurons;
Neuroinflammation;
Parkinson's disease
- MeSH:
Animals;
Dopaminergic Neurons/pathology*;
Mice;
Mice, Inbred C57BL;
Parkinson Disease/pathology*;
Parkinsonian Disorders/chemically induced*;
Substantia Nigra
- From:
Chinese Journal of Natural Medicines (English Ed.)
2022;20(2):111-119
- CountryChina
- Language:English
-
Abstract:
Parkinson's disease (PD) is a multifactorial disorder of the nervous system where a progressive loss of dopaminergic neurons exist. However, the pathogenesis of PD remains undefined, which becomes the main limitation for the development of clinical PD treatment. Demethylenetetrahydroberberine (DMTHB) is a novel derivative of natural product berberine. This study was aimed to explore the neuroprotective effects and pharmacological mechanism of DMTHB on Parkinson's disease using C57BL/6 mice. A PD model of mice was induced by administration of MPTP (20 mg·kg-1) and probenecid (200 mg·kg-1) twice per week for five weeks. The mice were administered with DMTHB daily by gavage at the dose of 5 and 50 mg·kg-1 for one- week prophylactic treatment and five-week theraputic treatment. The therapeutic effects of DMTHB were evaluated by behavior tests (the open field, rotarod and pole tests), immunohistochemical staining of tyrosine hydroxylase (TH), Nissl staining and biochemical assays. The molecular mechanisms of DMTHB on the key biomarkers of PD pathological states were analyzed by Western blot (WB) and qRT-PCR. DMTHB treatment alleviated the behavioral disorder induced by MPTP-probenecid. Nissl staining and TH staining showed that the damage of dopaminergic neurons in the substantia nigra was remarkably suppressed by DMTHB treatment. Western blot results showed that the ratio of Bcl-2/Bax and TH increased, but the level of α-synuclein (α-syn) was remarkably reduced, which indicated that the apoptosis of dopaminergic neurons in mice was significantly reduced. The protein phosphorylation of p-PI3K, p-AKT and p-mTOR also increased about 2-fold, compared with the model group. Furthermore, qRT-PCR results demonstrated that the mRNA levels of pro-inflammatory cytokines, IL-1β and TNF-α, were reduced, but the level of anti-inflammatory cytokine IL-10 increased after DMTHB treatment. Finally, the cellular assay displayed that DMTHB was also a strong antioxidant to protect neuron cell line PC12 by scavenging ROS. In this study, we demonstrated DMTHB alleviates the behavioral disorder and protects dopaminergic neurons through multiple-target effects includubg anti-apoptotic, anti-inflammatory and antioxidant effects.
